Acrivon Advances ACR-2316 into Randomized Dose Expansion with Durable Lung Cancer Responses — Acrivon Therapeutics, Inc.

Event summary

ACR-2316, a WEE1/PKMYT1 inhibitor, enters randomized dose expansion in Phase 1/2 study after showing durable responses in heavily pretreated lung cancer patients.
Selected doses of 120 mg and 160 mg QD (3 days on/4 days off weekly schedule) demonstrated favorable safety profile with limited hematological adverse events.
Expansion cohort will evaluate biomarker-selected solid tumors including SCLC, sqNSCLC, adNSCLC, endometrial, cervical, and esophago-gastric junction cancers.
Study adheres to FDA’s Project Optimus principles for dose optimization based on efficacy and safety data.

The big picture

Acrivon’s advancement of ACR-2316 reflects the growing emphasis on precision oncology and biomarker-driven development. The study’s adherence to FDA’s Project Optimus underscores a shift toward data-driven dose optimization, potentially setting a new standard for clinical trial design in oncology.

What we're watching

Clinical Efficacy: Whether ACR-2316 can sustain durable responses across multiple tumor types beyond lung cancer.
Regulatory Pathway: The pace at which Acrivon advances ACR-2316 toward pivotal trials under FDA’s Project Optimus framework.
Competitive Positioning: How Acrivon differentiates ACR-2316 in a crowded oncology space with its AP3 platform-driven design.